Cargando…
5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report
BACKGROUND: The loss of CD20 protein expression after a rituximab-containing regimen is one of the resistance mechanisms in non-Hodgkin's lymphoma. Recently, it was reported that 5-azacitidine administration upregulates the expression of CD20 in CD20-negative B-cell acute lymphoblastic leukemia...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739428/ https://www.ncbi.nlm.nih.gov/pubmed/26838941 http://dx.doi.org/10.1186/s13256-016-0809-7 |
_version_ | 1782413747790282752 |
---|---|
author | Tsutsumi, Yutaka Ohigashi, Hiroyuki Ito, Shinichi Shiratori, Souichi Teshima, Takanori |
author_facet | Tsutsumi, Yutaka Ohigashi, Hiroyuki Ito, Shinichi Shiratori, Souichi Teshima, Takanori |
author_sort | Tsutsumi, Yutaka |
collection | PubMed |
description | BACKGROUND: The loss of CD20 protein expression after a rituximab-containing regimen is one of the resistance mechanisms in non-Hodgkin's lymphoma. Recently, it was reported that 5-azacitidine administration upregulates the expression of CD20 in CD20-negative B-cell acute lymphoblastic leukemia. Here we report a similar upregulation in a patient with follicular lymphoma who was treated with 5-azacitidine against secondary myelodysplastic syndrome. CASE PRESENTATION: A 69-year-old Japanese woman with follicular lymphoma with treatment-related myelodysplastic syndrome was negative for the CD20 antibody at the time of her relapse. After treatment of 5-azacytidine for her myelodysplastic syndrome, CD20 expression was upregulated in the follicular lymphoma cells in her peripheral blood. We also observed follicular lymphoma cell stimulation in her peripheral blood due to 5-azacytidine. CONCLUSIONS: Although partial, CD20 expression was upregulated after treatment with 5-azacitidine. However, CD20 expression was not re-upregulated after a second administration of 5-azacitidine and we also observed the risk of lymphoma cell stimulation due to 5-azacitidine. |
format | Online Article Text |
id | pubmed-4739428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47394282016-02-04 5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report Tsutsumi, Yutaka Ohigashi, Hiroyuki Ito, Shinichi Shiratori, Souichi Teshima, Takanori J Med Case Rep Case Report BACKGROUND: The loss of CD20 protein expression after a rituximab-containing regimen is one of the resistance mechanisms in non-Hodgkin's lymphoma. Recently, it was reported that 5-azacitidine administration upregulates the expression of CD20 in CD20-negative B-cell acute lymphoblastic leukemia. Here we report a similar upregulation in a patient with follicular lymphoma who was treated with 5-azacitidine against secondary myelodysplastic syndrome. CASE PRESENTATION: A 69-year-old Japanese woman with follicular lymphoma with treatment-related myelodysplastic syndrome was negative for the CD20 antibody at the time of her relapse. After treatment of 5-azacytidine for her myelodysplastic syndrome, CD20 expression was upregulated in the follicular lymphoma cells in her peripheral blood. We also observed follicular lymphoma cell stimulation in her peripheral blood due to 5-azacytidine. CONCLUSIONS: Although partial, CD20 expression was upregulated after treatment with 5-azacitidine. However, CD20 expression was not re-upregulated after a second administration of 5-azacitidine and we also observed the risk of lymphoma cell stimulation due to 5-azacitidine. BioMed Central 2016-02-02 /pmc/articles/PMC4739428/ /pubmed/26838941 http://dx.doi.org/10.1186/s13256-016-0809-7 Text en © Tsutsumi et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Tsutsumi, Yutaka Ohigashi, Hiroyuki Ito, Shinichi Shiratori, Souichi Teshima, Takanori 5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report |
title | 5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report |
title_full | 5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report |
title_fullStr | 5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report |
title_full_unstemmed | 5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report |
title_short | 5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report |
title_sort | 5-azacytidine partially restores cd20 expression in follicular lymphoma that lost cd20 expression after rituximab treatment: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739428/ https://www.ncbi.nlm.nih.gov/pubmed/26838941 http://dx.doi.org/10.1186/s13256-016-0809-7 |
work_keys_str_mv | AT tsutsumiyutaka 5azacytidinepartiallyrestorescd20expressioninfollicularlymphomathatlostcd20expressionafterrituximabtreatmentacasereport AT ohigashihiroyuki 5azacytidinepartiallyrestorescd20expressioninfollicularlymphomathatlostcd20expressionafterrituximabtreatmentacasereport AT itoshinichi 5azacytidinepartiallyrestorescd20expressioninfollicularlymphomathatlostcd20expressionafterrituximabtreatmentacasereport AT shiratorisouichi 5azacytidinepartiallyrestorescd20expressioninfollicularlymphomathatlostcd20expressionafterrituximabtreatmentacasereport AT teshimatakanori 5azacytidinepartiallyrestorescd20expressioninfollicularlymphomathatlostcd20expressionafterrituximabtreatmentacasereport |